Bavarian Nordic A/S: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Bavarian Nordic A/S Issues FY 2013 Financial Guidance Above Analysts' Estimates; Proposes No FY 2012 Dividend
Bavarian Nordic A/S announced that for fiscal year 2013 it expects revenue at the level of DKK 1,100 million and a break-even result before tax. According to I/B/E/S estimates, analysts on average are expecting the Company to report fiscal year 2013 revenue of DKK 904.72 million and fiscal year 2013 pre-tax profit of negative DKK 69.88 million. The Company also announced that its Board of Directors will propose to the Annual General Meeting on April 17, 2013 that no dividends be paid for fiscal year 2012.
Latest Developments for Bavarian Nordic A/S
Latest Key Developments in Pharmaceuticals
- OPKO acquires dry powder inhaler to treat respiratory disorders
- American Capital receives $210 mln from sale of SPL Acquisition Corp to Shenzhen Hepalink Pharmaceutical Co., Ltd
- Akorn Inc completes acquisition of Hi-Tech Pharmacal Co Inc
- Recordati Industria Chimica E Farmaceutica SpA approves FY 2013 dividend; renews share buyback
- Share this
- Digg this